Diagnosis and surgical treatment of differentiated thyroid carcinoma in 40 years

doi:10.3760/cma.j.cn371439-20200623-00056

Abstract

Abstract:

Differentiated thyroid cancer (DTC) is the most common type of thyroid cancer. Most of patients with DTC are characterized by low invasiveness and good prognosis. With the development of medical imaging, fine needle biopsy and molecular biology technology, especially the progress of surgical technology, the early diagnosis rate of DTC and the survival rate after operation are significantly increased. However, the cognition understanding of DTC and some views of surgical treatment are still controversial. A systematic review and summary of the diagnosis and surgical treatment of DTC are made based on the changes in the past 40 years, especially the treatment strategy, surgical resection scope and indications of DTC primary focus and cervical lymph node metastasis, in order to propose a more reasonable and accurate individual diagnosis and treatment plan for patients with DTC.

Key words: Thyroid neoplasms, Lymph node excision, Thyroid surgery

Hou Xiaofeng, Xue Jincai, Tian Youxin, Liu Qinjiang. Diagnosis and surgical treatment of differentiated thyroid carcinoma in 40 years[J]. Journal of International Oncology, 2020, 47(8): 449-456.

References 63

[1]	Papaleontiou M, Haymart MR. Thyroid nodules and cancer during pregnancy, post-partum and preconception planning: addressing the uncertainties and challenges[J]. Best Pract Res Clin Endocrinol Metab, 2019: 101363. DOI: 10.1016/j.beem.2019.101363.
[2]	Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019,30(12):1856-1883. DOI: 10.1093/annonc/mdz400. doi: 10.1093/annonc/mdz400 pmid: 31549998
[3]	National Cancer Institute. SEER cancer statistics review, 1975—2010[EB/OL]. (2013-06-14) [2016-10-20]. http://seer.cancer.gov/csr/1975-2010/.
[4]	Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016,26(1):1-133. DOI: 10.1089/thy.2015.0020. doi: 10.1089/thy.2015.0020 pmid: 26462967
[5]	滕卫平. 甲状腺疾病诊治现代进展[J]. 中国实用内科杂志, 2019,39(4):311-315. DOI: 10.19538/j.nk2019040101.
[6]	赵月娥, 郑柏, 甘连州. 甲状腺癌的超声表现与病理对照分析[J]. 癌症进展, 2019,17(14):1697-1700. DOI: 10.11877/j.issn.1672-1535.2019.17.14.22.
[7]	Samir AE. The role and value of ultrasound elastography in the evaluation of theyropid nodules[J]. Cancer Cytopathol, 2016,124(11):765-766. DOI: 10.1002/cncy.21782. doi: 10.1002/cncy.21782 pmid: 27779819
[8]	中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J]. 中国肿瘤临床, 2016,43(10):405-411. DOI: 10.3969/j.issn.1000-8179.2016.10.001.
[9]	中华人民共和国国家卫生健康委员会. 甲状腺癌诊疗规范(2018年版)[J/CD]. 中华普通外科学文献(电子版), 2019,13(1):1-15. DOI: 10.3877/cma.j.issn.1674-0793.2019.01.001.
[10]	王志军, 李玉龙, 彭德峰, 等. 甲状腺微小癌262例临床分析[J]. 中国普通外科杂志, 2016,25(11):1557-1562. DOI: 10.3978/j.issn.1005-6947.2016.11.006.
[11]	Ophir J, Céspedes I, Ponnekanti H, et al. Elastography: a quantitative method for imaging the elasticity of biological tissues[J]. Ultrason Imaging, 1991,13(2):111-134. DOI: 10.1177/016173469101300201. pmid: 1858217
[12]	Cantisani V, Maceroni P, D'Andrea V, et al. Strain ratio ultrasound elastography increases the accuracy of colour-Doppler ultrasound in the evaluation of Thy-3 nodules. A bi-centre university experience[J]. Eur Radiol, 2016,26(5):1441-1449. DOI: 10.1007/s00330-015-3956-0. doi: 10.1007/s00330-015-3956-0 pmid: 26337431
[13]	Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management[J]. J Clin Endocrinol Metab, 2009,94(5):1748-1751. DOI: 10.1210/jc.2008-1724. doi: 10.1210/jc.2008-1724 pmid: 19276237
[14]	Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk[J]. Radiology, 2011,260(3):892-899. DOI: 10.1148/radiol.11110206. pmid: 21771959
[15]	陈正雷, 罗平, 王全江, 等. TI-RADS对甲状腺良恶性结节的诊断效能及一致性分析[J]. 中国临床医学影像杂志, 2019,30(12):837-840. DOI: 10.12117/jccmi.2019.12.001.
[16]	林友国, 陈梅青, 林霞蓉, 等. 甲状腺结节TI-RADS分类结果分析[J]. 医学影像学杂志, 2019,29(8):1297-1300.
[17]	Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee[J]. J Am Coll Radiol, 2018,15(3 Pt A):381-382. DOI: 10.1016/j.jacr.2017.12.035. doi: 10.1016/j.jacr.2017.12.035 pmid: 29396195
[18]	李青颖, 孙志宇, 侯晓东, 等. 超声弹性成像联合三维超声对甲状腺良恶结节的鉴别诊断的临床研究[J]. 世界最新医学信息文摘, 2019,19(63):243-244. DOI: 10.19613/j.cnki.1671-3141.2019.63.135.
[19]	李长霖, 周乐, 孙辉. 我国甲状腺结节细针穿刺活检技术应用现状及进展[J]. 中国实用外科杂志, 2020,40(2):195-198. DOI: 10.19538/j.cjps.issn1005-2208.2020.02.13.
[20]	Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology[J]. Thyroid, 2017,27(11):1341-1346. DOI: 10.1089/thy.2017.0500. doi: 10.1089/thy.2017.0500 pmid: 29091573
[21]	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009,19(11):1167-1214. DOI: 10.1089/thy.2009.0110. doi: 10.1089/thy.2009.0110 pmid: 19860577
[22]	Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018,6(5):e555-e567. DOI: 10.1016/S2214-109X(18)30127-X. pmid: 29653628
[23]	Ho AS, Davies L, Nixon IJ, et al. Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates[J]. Cancer, 2015,121(11):1793-1799. DOI: 10.1002/cncr.29289. pmid: 25712809
[24]	DeLellis RA, Lloyd RV, Heitz PU, et al. WHO classification of tumours,pathology and genetics of tumours of endocrine organs[M]. 2nd ed. Lyon: IARC Press, 2004: 56-70.
[25]	高明, 葛明华. 甲状腺肿瘤学[M]. 北京: 人民卫生出版社, 2018: 316-320.
[26]	伊丹丹, 黄韬, 宋鹏, 等. 甲状腺微小乳头状癌手术方式对肿瘤复发影响的meta分析[J]. 东南大学学报(医学版), 2017,36(1):48-52. DOI: 10.3969/j.issn.1671-6264.2017.01.012.
[27]	李树玲. 头颈肿瘤诊断、治疗及预后[M]. 天津: 天津科学技术出版社, 1983: 319-324.
[28]	Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American thyroid association[J]. Arch Intern Med, 1996,156(19):2165-2172. pmid: 8885814
[29]	Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2006,16(2):109-142. DOI: 10.1089/thy.2006.16.109. doi: 10.1089/thy.2006.16.109 pmid: 16420177
[30]	Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy[J]. Surgery, 2012,151(4):571-579. DOI: 10.1016/j.surg.2011.08.016. doi: 10.1016/j.surg.2011.08.016 pmid: 22001636
[31]	Barney BM, Hitchcock YJ, Sharma P, et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer[J]. Head Neck, 2011,33(5):645-649. DOI: 10.1002/hed.21504. pmid: 20687168
[32]	Mendelsohn AH, Elashoff DA, Abemayor E, et al. Surgery for papillary thyroid carcinoma: is lobectomy enough?[J]. Arch Otolaryngol Head Neck Surg, 2010,136(11):1055-1061. DOI: 10.1001/archoto.2010.181. doi: 10.1001/archoto.2010.181 pmid: 21079156
[33]	Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases[J]. World J Surg, 2014,38(1):68-79. DOI: 10.1007/s00268-013-2224-1. pmid: 24081532
[34]	Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy[J]. Surgery, 2012,151(4):571-579. DOI: 10.1016/j.surg.2011.08.016. doi: 10.1016/j.surg.2011.08.016 pmid: 22001636
[35]	中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华内分泌代谢杂志, 2012,28(10):779-797. DOI: 10.3760/cma.j.issn.1000-6699.2012.10.002. doi: 10.3760/cma.j.issn.1000-6699.2012.10.002
[36]	Donatini G, Castagnet M, Desurmont T, et al. Partial thyroidectomy for papillary thyroid microcarcinoma: is completion total thyroidectomy indicated?[J]. World J Surg, 2016,40(3):510-515. DOI: 10.1007/s00268-015-3327-7. doi: 10.1007/s00268-015-3327-7 pmid: 26546190
[37]	Dralle H, Musholt TJ, Schabram J, et al. German association of endocrine surgeons practice guideline for the surgical management of malignant thyroid tumors[J]. Langenbecks Arch Surg, 2013,398(3):347-375. DOI: 10.1007/s00423-013-1057-6. doi: 10.1007/s00423-013-1057-6 pmid: 23456424
[38]	Liu Z, Huang T. Papillary thyroid microcarcinoma: an over-treated malignancy?[J]. World J Surg, 2016,40(3):764-765. DOI: 10.1007/s00268-015-3244-9. doi: 10.1007/s00268-015-3244-9 pmid: 26316118
[39]	Back K, Kim JS, Kim JH, et al. Superior located papillary thyroid microcarcinoma is a risk factor for lateral lymph node metastasis[J]. Ann Surg Oncol, 2019,26(12):3992-4001. DOI: 10.1245/s10434-019-07587-2. doi: 10.1245/s10434-019-07587-2 pmid: 31264121
[40]	Cho SY, Lee TH, Ku YH, et al. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia[J]. Surgery, 2015,157(1):111-118. DOI: 10.1016/j.surg.2014.05.023. doi: 10.1016/j.surg.2014.05.023 pmid: 25444224
[41]	Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation[J]. Thyroid, 2014,24(1):27-34. DOI: 10.1089/thy.2013.0367. doi: 10.1089/thy.2013.0367 pmid: 24001104
[42]	Oda H, Miyauchi A, Ito Y, et al. Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery[J]. Thyroid, 2016,26(1):150-155. DOI: 10.1089/thy.2015.0313. doi: 10.1089/thy.2015.0313 pmid: 26426735
[43]	Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papi-llary thyroid microcarcinoma in Japanese patients[J]. World J Surg, 2010,34(1):28-35. DOI: 10.1007/s00268-009-0303-0. doi: 10.1007/s00268-009-0303-0 pmid: 20020290
[44]	Palme CE, Waseem Z, Raza SN, et al. Management and outcome of recurrent well-differentiated thyroid carcinoma[J]. Arch Otolaryngol Head Neck Surg, 2004,130(7):819-824. DOI: 10.1001/archotol.130.7.819. doi: 10.1001/archotol.130.7.819 pmid: 15262757
[45]	Sugitani I, Fujimoto Y, Yamada K. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma[J]. World J Surg, 2014,38(3):673-678. DOI: 10.1007/s00268-013-2335-8. doi: 10.1007/s00268-013-2335-8
[46]	Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance[J]. JAMA Otolaryngol Head Neck Surg, 2017,143(10):1015-1020. DOI: 10.1001/jamaoto.2017.1442. doi: 10.1001/jamaoto.2017.1442 pmid: 28859191
[47]	Miyauchi A, Ito Y, Oda H. Insights into the management of papi-llary microcarcinoma of the thyroid[J]. Thyroid , 2018,28(1):23-31. DOI: 10.1089/thy.2017.0227. doi: 10.1089/thy.2017.0227 pmid: 28629253
[48]	Mehanna H, AI-Maqbili T, Carter B, et al. Differences in the recu-rrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21329 person-years of follow-up[J]. J Clin Endocrinol Metab, 2014,99(8):2834-2843. DOI: 10.1210/jc.2013-2118. doi: 10.1210/jc.2013-2118 pmid: 24828487
[49]	Chiacchio S, Lorenzoni A, Boni G, et al. Anaplastic thyroid cancer: prevalence, diagnosis and treatment[J]. Minerva Endocrinol, 2008,33(4):341-357. pmid: 18923370
[50]	Hüscher CS, Chiodini S, Napolitano C, et al. Endoscopic right thyroid lobectomy[J]. Surg Endosc, 1997,11(8):877. DOI: 10.1007/s004649900476. doi: 10.1007/s004649900476 pmid: 9266657
[51]	李宝元, 郭雅文. 腔镜甲状腺手术的研究进展[J]. 腹腔镜外科杂志, 2020,25(4):312-315. DOI: 10.13499/j.cnki.fqjwkzz.2020.04.312.
[52]	Chéreau N, Buffet C, Trésallet C, et al. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: predictive factors and operative management[J]. Surgery, 2016,159(3):755-762. DOI: 10.1016/j.surg.2015.08.033. doi: 10.1016/j.surg.2015.08.033 pmid: 26435440
[53]	Gambardella C, Tartaglia E, Nunziata A, et al. Clinical significance of prophylactic central compartment neck dissection in the treatment of clinically node-negative papillary thyroid cancer patients[J]. World J Surg Oncol, 2016,14(1):247. DOI: 10.1186/s12957-016-1003-5. doi: 10.1186/s12957-016-1003-5 pmid: 27644091
[54]	Hennessy M, Goldenberg D. The role of prophylactic central neck dissection in the treatment of differentiated thyroid cancer[J]. Rambam Maimonides Med J, 2016,7(1):e0007. DOI: 10.5041/RMMJ.10234. doi: 10.5041/RMMJ.20769172
[55]	Conzo G, Tartaglia E, Avenia N, et al. Role of prophylactic central compartment lymph node dissection in clinically N₀ differentiated thyroid cancer patients: analysis of risk factors and review of modern trends[J]. World J Surg Oncol, 2016,14:149. DOI: 10.1186/s12957-016-0879-4. pmid: 27185169
[56]	Ywata de Carvalho A, Chulam TC, Kowalski LP. Long-term results of observation vs prophylactic selective level vi neck dissection for papillary thyroid carcinoma at a cancer center[J]. JAMA Otolaryngol Head Neck Surg, 2015,141(7):599-606. DOI: 10.1001/jamaoto.2015.0786. doi: 10.1001/jamaoto.2015.0786 pmid: 25997016
[57]	Giordano D, Frasoldati A, Gabrielli E, et al. Long-term outcomes of central neck dissection for cN₀ papillary thyroid carcinoma[J]. Am J Otolaryngol, 2017,38(5):576-581. DOI: 10.1016/j.amjoto.2017.06.004. pmid: 28599790
[58]	De Crea C, Raffaelli M, Sessa L, et al. Surgical approach to level Ⅵ in papillary thyroid carcinoma: an overview[J]. Updates Surg, 2017,69(2):205-209. DOI: 10.1007/s13304-017-0468-2. doi: 10.1007/s13304-017-0468-2 pmid: 28612210
[59]	Dubernard X, Dabakuyo S, Ouedraogo S, et al. Prophylactic neck dissection for low-risk differentiated thyroid cancers: risk-benefit analysis[J]. Head Neck, 2016,38(7):1091-1096. DOI: 10.1002/hed.24402. pmid: 26873677
[60]	Kim JW, Roh JL, Gong G, et al. Recurrence in patients with clinically early-stage papillary thyroid carcinoma according to tumor size and surgical extent[J]. Am J Surg, 2016, 212(3): 419-425.e1. DOI: 10.1016/j.amjsurg.2015.12.015. doi: 10.1016/j.amjsurg.2015.12.015 pmid: 27002954
[61]	Agrawal N, Evasovich MR, Kandil E, et al. Indications and extent of central neck dissection for papillary thyroid cancer: an American head and neck society consensus statement[J]. Head Neck, 2017,39(7):1269-1279. DOI: 10.1002/hed.24715. doi: 10.1002/hed.24715 pmid: 28449244
[62]	Mulla M, Schulte KM. Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment[J]. Clin Endocrinol (Oxf), 2012,76(1):131-136. DOI: 10.1111/j.1365-2265.2011.04162.x. doi: 10.1111/cen.2011.76.issue-1
[63]	黄志刚, 陈晓红. 分化型甲状腺癌个体化分层治疗的策略和意义[J]. 中华耳鼻咽喉头颈外科杂志, 2017,52(6):405-409. DOI: 10.3760/cma.j.issn.1673-0860.2017.06.002.